Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
about
New drugs for prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012Oligometastatic Prostate CancerMeta-analysis of individual patient data from randomized trials: a review of methods used in practice.Hormonal therapy for prostate cancer: past, present and future.An evaluation of bicalutamide in the treatment of prostate cancer.Hormonal treatment for prostate cancer.Bicalutamide (Casodex) in the treatment of prostate cancer.SEOM clinical guidelines for the treatment of metastatic prostate cancerBicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer.Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.Controversies surrounding androgen deprivation for prostate cancer.Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells.Risk stratification in the hormonal treatment of patients with prostate cancerHormone therapy in the management of prostate cancer: evidence-based approachesThe androgen receptor: structure, mutations, and antiandrogens.Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer.Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer.Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer.Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility.New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.Recombinant disintegrin domain of human ADAM9 inhibits migration and invasion of DU145 prostate tumor cellsProstate cancer and the principles of hormone therapy.First Brazilian Consensus of Advanced Prostate Cancer: Recommendations for Clinical Practice.Side-effects of treatments for locally advanced prostate cancer.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceManagement of prostate cancer. Part 3: metastatic disease.The changing pattern of management for hormone-refractory, metastatic prostate cancer.Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments.Evolving treatment paradigms for locally advanced and metastatic prostate cancer.Is hormone ablation still the right choice for advanced prostate cancer?Multiple intracrine hormonal targets in the prostate: opportunities and challenges.Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
P2860
Q26827515-026B7BE0-2696-48B1-A99A-A5B9D0F4273AQ27022847-211D3C1F-8DA5-4B49-9828-E26DFC658ED5Q28075182-4E353B2C-C92F-430B-88D6-D1D7BBD5185BQ31016826-1B12A2F8-E9F6-48F9-899D-29DC033B7F15Q34138275-231649E9-1765-4EA9-9FDA-24787B451558Q34145167-4C790E0B-A5B6-4FAB-BF2E-FEF7848B425BQ34167174-EF6056A2-07FC-4E90-B3EB-A401EEB54DA2Q34293191-7B977C36-ADC9-4764-9D9C-261F00B58192Q34553405-DF0E3A72-D6D5-40CD-8AFA-12DDDCB1D309Q34596863-0D6803CE-42C5-48D1-A369-74C6141042EAQ34720933-DECF332A-A4DA-4102-B48E-A29EC37F639CQ34747437-7B124797-C1D4-4A51-B069-1CE2ADA83574Q34849222-83D135AF-B4F8-4057-91FC-BB78FE7AD602Q34982106-045172E6-6DF9-4D15-8978-3B80DB0FC787Q35076189-55A8E1C1-21B1-4A09-8EE0-05F0788B02A7Q35076432-D3D84303-B5E9-455B-ABAF-C7E5C2514303Q35193278-086CFF45-8B91-42FC-8894-DECE9EBBC6E1Q35619547-813BC91F-15DC-4299-BDC0-530ED8CAFC7BQ35738188-278254D3-860C-491E-8F3D-B5770E8F671AQ35879087-6C4ABD68-14A9-4994-8435-05AC671E7B14Q35906945-E292CD9E-43FF-4D2E-B7B6-09869F4B8569Q35929058-8792B253-3BAC-4109-A0E3-7AC56A230284Q35967325-93239191-DC90-4D77-8695-824F30BE1BFEQ36023678-F23BAE96-F774-407C-B488-E304E9B1C40BQ36039229-5EF58F25-3797-4D41-8FEA-182B3FACFBAAQ36066144-A408C91B-E264-42B3-8BF9-0C9D3D1CB464Q36124854-9228FE3B-1301-461C-A9ED-655942A496CCQ36143973-FF198749-2E03-4612-BC36-0A91EBFCC6C9Q36280995-168C221E-E2E9-490F-A566-5A23127A3D2CQ36335068-397651E5-0711-445D-BFF8-A0E25042F535Q36381291-47A7131C-94C7-42F5-B389-C43ABDE1AD58Q36470627-2E8D594F-270C-4EEA-83C9-81D69D4372DCQ36499259-A3EACF3A-3CD5-4902-86CB-2DD855B2163FQ36519880-D76DBDC3-BFEF-4B79-943C-A822E0A28CD2Q36573874-7022777F-C5FE-42E3-ACB2-28C2355D1EB6Q36668260-FE3188E0-883A-4260-BFF4-B8F12CB5E9A3Q36861765-FD2AEBE7-DEC6-45FB-AAF4-FF17DA05454FQ36861779-7B8457E1-20BF-40BF-AF93-3709E4DD5C25Q37028339-08F7A3EA-56B1-4996-8D7F-5213A5E63DF7Q37134564-602DC451-B407-4878-B35D-E38995958CCB
P2860
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
description
article publié dans la revue scientifique The Lancet
@fr
im April 2000 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2000
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Maximum androgen blockade in a ...... rview of the randomised trials
@en
Maximum androgen blockade in a ...... rview of the randomised trials
@nl
type
label
Maximum androgen blockade in a ...... rview of the randomised trials
@en
Maximum androgen blockade in a ...... rview of the randomised trials
@nl
prefLabel
Maximum androgen blockade in a ...... rview of the randomised trials
@en
Maximum androgen blockade in a ...... rview of the randomised trials
@nl
P1433
P1476
Maximum androgen blockade in a ...... rview of the randomised trials
@en
P304
P356
10.1016/S0140-6736(00)02163-2
P407
P577
2000-04-01T00:00:00Z